Two years post affordable medicines facility for malaria program: availability and prices of anti-malarial drugs in central Ghana. by Freeman, Alexander et al.
Freeman, Alexander; Kwarteng, Anthony; Febir, Lawrence Gyabaa;
Amenga-Etego, Seeba; Owusu-Agyei, Seth; Asante, Kwaku Poku
(2017) Two years post affordable medicines facility for malaria pro-
gram: availability and prices of anti-malarial drugs in central Ghana.
Journal of pharmaceutical policy and practice, 10 (1). p. 15. ISSN
2052-3211 DOI: https://doi.org/10.1186/s40545-017-0103-0
Downloaded from: http://researchonline.lshtm.ac.uk/4651286/
DOI: 10.1186/s40545-017-0103-0
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH Open Access
Two years post affordable medicines facility
for malaria program: availability and prices
of anti-malarial drugs in central Ghana
Alexander Freeman1,2, Anthony Kwarteng2, Lawrence Gyabaa Febir2, Seeba Amenga-Etego2, Seth Owusu-Agyei2
and Kwaku Poku Asante2*
Abstract
Background: The Affordable Medicines Facility for malaria (AMFm) Program was a subsidy aimed at artemisinin-
based combination therapies (ACTs) in order to increase availability, affordability, and market share of ACTs in 8
malaria endemic countries in Africa. The WHO supervised the manufacture of the subsidized products, named them
Quality Assured ACTs (QAACT) and printed a Green Leaf Logo on all QAACT packages. Ghana began to receive the
subsidized QAACTs in 2010.
Methods: A cross-sectional stock survey was conducted at 63 licensed chemical shops (LCS) and private
pharmacies in two districts of the Brong-Ahafo region of Ghana to determine the availability and price of all anti-
malarial treatments. Drug outlets were visited over a 3-weeks period in October and November of 2014, about 2
years after the end of AMFm program.
Results: At least one QAACT was available in 88.9% (95% CI 80.9% – 96.8%) of all drug outlets with no difference
between urban and rural locations. Non-Assured ACTs (NAACT) were significantly more available in urban drug outlets
[75.0% availability (95% CI 59.1% – 90.9%)] than in rural drug outlets [16.1% availability (95% CI 2.4% – 29.9%)]. The top
selling product was Artemether Lumefantrine with the Green Leaf Logo, a QAACT. There was a significant difference in
the mean price of a QAACT [$1.04 USD (95% CI $0.98 – $1.11)], and the mean price of a NAACT in both the urban and
rural areas [$2.46 USD (95% CI $2.11 – $2.81)]. There was no significant difference in the price of any product that was
available in urban and rural settings
Conclusion: About 2 years after the AMFm program, subsidized QAACTs in Ghana were widely available and more
affordable than NAACTs in the Kintampo North District and Kintampo South Municipality of Ghana. The AMFm
program appeared to have mostly succeeded in making QAACTs available and affordable.
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Background
In 2012, there were an estimated 207 million cases and
627,000 deaths due to malaria worldwide. Approximately
90% of these deaths occurred in Sub-Saharan Africa [1].
In Ghana, 100% of the population is at risk for year-
round transmission of the deadliest strain of malaria,
Plasmodium falciparum [2]. The burden of malaria is
high in Ghana, with about 323 cases per 1000 children
under 5 years old per year [3]. In central Ghana, where
the Kintampo North Municipality and the Kintampo
South District are located, individuals experience ap-
proximately 269 malaria infective bites per person per
year. The annual prevalence of malaria is 58% among all
ages in the Kintampo District [2].
The National Malaria Control Program of Ghana, in an
effort to reach their goal of a 75% reduction in malaria
morbidity and mortality by 2015, outlined a strategy that
included the primary use of Artemisinin Combination
Therapies (ACTs) such as Artesunate Amodiaquine
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(ASAQ) and Artemether Lumefantrine (AL) for the treat-
ment of malaria [4].
ASAQ and AL are artemisinin-based combination
therapies with a high therapeutic efficacy [5]. However,
the cost is prohibitively high for many Africans [6].
Other drugs used to control malaria in Ghana includes
quinine and Sulphadoxine – Pyrimethamine (SP) which
are recommended for management of severe malaria
and for Intermittent Preventive Treatment in Pregnancy
(IPTp), respectively [7].
Private pharmacies and licensed chemical shops are
often the first point of care for many Sub-Saharan
Africans, who do not visit a hospital or clinic until after
initial self-treatment has failed [8]. In the Kintampo re-
gion, awareness of the causes of malaria was high but
awareness of the first-line treatment, ASAQ, was low [9].
In Ghana, ACTs are sold over the counter in both li-
censed chemical shops (LCS) and pharmacies. A phar-
macy is manned by a registered pharmacist that serve
medications based on prescriptions as well as over the
counter drugs such as the anti-malarial treatments de-
scribed in this study. A LCS is manned by a community
members who cannot sell prescribed medications but can
sell the anti-malarial treatments that are described in this
study over the counter as well. For the remainder of this
study, pharmacies and LCS are referred to as drug outlets.
It was estimated that in 2009, 91.7% of all ACTs imported
into Ghana was by the private sector where public facil-
ities often procured their medication [10]. The supply of
ACTs to public facilities from the private sector may have
been driven by inadequate government funds to import
ACTs through the public sector.
The Global Fund created the Affordable Medicines
Facility for malaria (AMFm) Program in 2010 as an
experimental financing mechanism in 8 pilot countries,
including Ghana, to increase the availability, affordabil-
ity, market share and use of ACTs. AMFm did not pro-
vide the products, nor was it involved in the naming or
them. The AMFm program provided the funds via a
subsidy to purchase only ACTs that they deemed effect-
ive. The products the AMFm program subsidized had a
Green Leaf logo on the package and are referred to in
this study as a Quality Assured ACT (QAACT). One
goal of AMFm was to match the price of a QAACT with
the cheaper treatments to push out the use of these less
effective options. The first subsidized drugs co-paid by
the Global Fund with the Green Leaf logo arrived in
Ghana in August 2010 [11].
An independent evaluation of the AMFm program
showed a significant impact of the program on the avail-
ability, price and market share of the subsidized
QAACTs across multiple countries [12, 13]. For in-
stance, the availability of QAACTs in Ghana increased
in both urban and rural areas by 52 and 35% respectively
[14]; the national average price of ACT decreased from
$3.42 to 1.13 per treatment in private facilities [11]; in
rural areas, the price of ACTs dropped from $2.74 to
0.94 [14]; the market share of QAACTs increased by
45.3% in private health facilities [14]. QAACTs were
found to have been available in remote areas of Ghana
at the completion of the AMFm program as well [15].
After the pilot program ended in December 2012, the
AMFm program was integrated into normal funding
procedures of The Global Fund and Ghana continued to
receive subsidized QAACTs from the Global Fund until
end of 2013 [16].
This research aimed to determine the state of the private
anti-malarial market in a predominantly rural area in
Ghana about 2 years after the completion of the AMFm
program. Specifically, the aims were to determine the
background of the drug outlet attendant decided which
medicine to recommend, the availability of all anti-
malarial products on the market and the mean price of
these anti-malarial products across drug outlets located in
the town centers, defined as Urban. and the outskirts of
the study area, defined as Rural.
Methods
Study area
The cross-sectional study was conducted in the Kintampo
North Municipality and Kintampo South District. The
study area is situated in the forest-savanna transitional
zone of the Brong-Ahafo region of Ghana. It covers an
area of 7,162 km2 with resident population of approxi-
mately 135,000 living in 22,000 homes spread among 97
communities as at 2009 [17]. The study area is predomin-
antly rural, similar to other areas in Ghana as defined by
the Kintampo Health Surveillance System [17]. Malaria is
the most common cause of illness in the area and over the
counter drugs from a drug outlet are one of the first treat-
ment methods febrile illness in Ghana [18]. A majority of
the population are peasant farmers, similar to other areas
of Ghana [17]. The study area was purposively selected
because of the presence of research infrastructure.
The towns of Kintampo, Babato and Jema are the
urban areas in the Kintampo North Municipality and
Kintampo South District. The drug outlets in these
towns were considered urban (n = 32) while all other
drug outlets were considered in a rural area (n = 31).
Drug outlet survey
The study took place from October 2014 to November
2014. A total of 67 drug outlets were included in the
study area. Three were private pharmacies and 64 were
operating licensed chemical shops (LCS). Only drug
outlets that were open at least 1 day per week, had a
permanent location and did not receive public funds to
operate were surveyed. Four drug outlets did not meet
Freeman et al. Journal of Pharmaceutical Policy and Practice  (2017) 10:15 Page 2 of 7
these criteria as they were permanently closed. A total of
63 drug outlets (60 LCSs and 3 Pharmacies) were
included in the analysis.
The locations of the drug outlets were distributed
across the entire Kintampo North Municipality and
South District.
Anti-malarial treatments were grouped into three cat-
egories. Quality Assured ACTs (QAACTs) are ACTs that
comply with the Global Fund’s ACT chemical regula-
tions and have a green leaf logo printed on its label.
Non-Assured ACTs (NAACTs) are ACTs without the
Green Leaf Logo e.g. AL, ASAQ and Dihydroartemisinin
Piperaquine (DHAP). Other treatments consisted of
Amodiaquine, Artesunate, Quinine and SP.
Trained fieldworkers administered a pretested ques-
tionnaire to the drug outlet attendants after they had
consented to participate in the study. Field workers
observed the physical product before marking it as avail-
able on the data collection tool. The methodology used
in assessing most popular anti-malarial treatment was
modeled on methodology described by Davis et. al [10].
Attendants then named the first, second and third most
popular anti-malarial chemical composition and its
brand over the previous 3 months. The prices of anti-
malarial products were determined by asking the drug
outlet attendant and observing their price list if they
existed. The data collection team was fluent in both
English and Twi, the local language.
Data management and statistical analysis
All data were double-entered using Microsoft Access
then transferred to Stata version 13 and R version 3.3.2
for cleaning, analysis and presentation. All products
were classified as Quality Assured or Non Assured (with
or without Green Leaf Logo) ACT or Other. The prod-
ucts presented are the equivalent of an adult equivalent
treatment dose.
Availability of anti-malarial treatments was expressed
as simple proportions. Top selling products were deter-
mined on a point-based ranking system. For each loca-
tion, the top selling product was assigned three points,
the second two points and the third one point. The
points for each product was summed, ranked and de-
scribed across urban and rural location. Simple propor-
tions available drugs were determined and the statistical
difference within subgroups (urban and rural) for their
availability were determined using chi-squared tests with
p-values preset at the .05 level. The price of anti-
malarial products were converted from Ghanaian Cedis
to U.S. Dollar using the interbank exchange rate at the
start of the collection period, October 27, 2014, at 3.2
Cedis = $1.00 USD. Prices are presented as the mean
price of each product from all drug outlets that had the
product available. The price of an unavailable product
was not collected. The data is presented for all drug out-
lets, and then disaggregated by drug outlets located in
urban and rural areas. Welch’s two sample t-tests was
used to test significant differences between the mean
price of QAACT and NAACT at p < .05 level of
significance.
Ethical consideration
Ethical approval was granted from the Kintampo Health
Research Centre institutional Review Committee (Federal
Wide Assurance number: FWA00011103) in Kintampo,
Ghana. All Licensed Chemical Shop and Pharmacy Atten-
dants were read the informed consent form and signed
before enrolling in the study. Data was stored on a
password protected computer and paper forms were
stored in a secure office.
Results
Demographics of drug outlet attendants
The average age of a drug outlet attendant was 41.9 years
(range: 18 – 73). There was no difference in the average
age of rural and urban attendants. A majority of drug
outlet attendants were male and there were more male
attendants in urban areas compared with rural areas
(Table 1). Urban drug outlet attendants had attained a
higher level of education. 81.3% of urban attendants had
completed secondary school while approximately half
(48.4%) of their rural counterparts had done the same.
Urban drug outlets had a higher rate of recording sales
in a physical book, with 84.4% of urban drug outlet
attendants able to show physical proof of the book.
There was no significant difference in the age, years of
experience in the industry, rate with professional drug-
dispensing certificate, or training in malaria treatment in
the past 6 months between rural and urban drug outlet
attendants. Of those who had attended a training, a ma-
jority of them went to one hosted by the local Pharmacy
Council.
Availability
There was a difference in the availability of QAACTs
when ungrouped into its two chemical compositions.
Quality Assured Artesunate – Amodiaquine (ASAQ)
was significantly more available in urban drug outlets
than rural drug outlets. 59.4% of urban drug outlets
stocked ASAQ with a Green Leaf logo while only 29.0%
of rural drug outlets did the same (Table 2). Quality
Assured Artemether – Lumefantrine was more available
in rural drug outlets, with 87.1% of rural drug outlets
having at least one treatment while 75.0% of urban drug
outlets doing the same. This finding was not significantly
different between urban and rural drug outlets, but it is
suggestive of the popularity of AL compared to ASAQ
in rural areas.
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Amodiaquine was significantly more available in
rural drug outlets than in urban drug outlets. 51.6%
of rural drug outlets had at least one dose of Amo-
diaquine in stock while 21.9% or urban drug outlets
did the same.
There was no significant difference in the availability of
Quinine or Sulphadoxine – Pyrimethamine between urban
and rural drug outlets. 39.7% of all drug outlets stocked
Quinine and 68.3% of all drug outlets stocked SP.
The total number of variations available was signifi-
cantly greater in urban drug outlets than in rural drug
outlets. In urban drug outlets, customers had a choice
between a mean of 6.19 products while customers at rural
drug outlets could choose from an average of 4.03
Table 1 Characteristics of Licensed Chemical Shop and Pharmaceutical Attendants in the Kintampo North Municipality and South
District
Variable Urban Shops Rural Shops All Shops
Number of Shops 32 31 63
Average Age (Range) 41.8 (20–73) 42.0 (18–65) 41.9 (18–73)
Experience in years (Range) 12.0 (2–30) 13.0 (1–30) 12.5 (1–30)
Gender %, Male 93.8 71.0 82.5
Type of Drug Outlet %, Licensed
Chemical Shop
90.6 100.0 95.2
Sales Record %, Keeps Record 84.4 51.6 68.3
Level of Education %, Above
Secondary Education
81.3 48.4 65.1
Professional Drug-Dispensing
Qualification %, Has Qualification
43.8 38.7 41.3
Malaria Treatment Trained in Past
6 Months %, Attended Training
84.3 71.0 77.8
Table 2 Availability of Anti-Malarial Products in the Kintampo North Municipality and South District
Product Urban Drug outlets Rural Drug outlets All Drug outlets
Drug outlets with Product
Available (%)
N = 32
Drug outlets with Product
Available (%)
N = 31
Drug outlets with Product
Available (%)
N = 63
Any QAACT 84.4 93.6 88.9
QA AL 75.0 87.1 81.0
QA ASAQ 59.4 29.0 44.4 *
Any NAACT 75.0 16.1 46.0 *
AL 71.9 12.9 42.9 *
ASAQ 21.9 0.0 11.1 *
DHAP 25.0 3.2 14.3 *
Any ACT 90.6 93.6 92.1
AL 84.4 90.3 87.3
ASAQ 68.8 29.0 50.8 *
DHAP 25.0 3.2 14.3 *
Any Other 81.3 80.6 80.6
Amodiaquine 21.9 51.6 36.5 *
Artesunate 0.0 3.2 1.6
Quinine 31.3 48.4 39.7
SP 71.9 64.5 68.3
Any Anti-Malarial 96.9 93.6 95.2
Total Number of Products Available 6.19 4.03 5.12 *
*Signifies chi-squared value between urban and rural groups is below p < .05 level of significance
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products. 95.2% of all drug outlets stocked at least one
anti-malarial product.
It is important to compare the availability of QAACTs
and NAACTs in both urban and rural areas as shown in
Table 3. QAACTs were significantly more available in
rural drug outlets than NAACTs. 93.6% of rural drug
outlets carried at least one QAACT while only 16.1% of
drug outlets carried a NAACT. There was no significant
difference between the availability of QAACTs and
NAACTs in urban drug outlets (Table 3).
The availability of QAACTs and NAACTs were differ-
ent as well. There was a significant difference between
the availability of any NAACTs and any QAACTS in
rural but not urban drug outlets. AL was the most
widely available product, Quality Assured or Non-
Assured. There was a large difference in the availability
of Quality Assured AL and Non-Assured AL in rural
areas. 87.1% of rural drug outlets had QA AL while only
12.9% had NA AL (Table 3). No rural drug outlet had
NA ASAQ available for sale.
Top sellers
Artemether Lumefantrine was the top selling anti-
malarial product sold in both urban and rural settings in
the study area. The top selling brand of this ACT was a
product of Ipca Laboratories, India, a Quality Assured
product with the Green Leaf logo. The second most
popular product differed between urban and rural drug
outlets. Quality Assured ASAQ was the second top sell-
ing anti-malarial treatment in urban drug outlets and SP
was the second top selling in rural drug outlets. Quinine
was the third top selling product in rural drug outlets
while it was rarely mentioned by attendants among
urban drug outlets.
Price
The mean price of a QAACT [$1.04 (95% CI $0.98 –
$1.11)] was significantly different and more than half the
price of a NAACT [$2.46 (95% CI $2.11 – $2.81)] (Table 4).
The mean price of a QAACT was slightly but significantly
more expensive than the mean price of the other combined
products [$0.90 (95% CI $0.78 – $1.01)]. The mean price of
Amodiaquine was $1.18 (95% CI $1.04 – $1.32), Quinine
was $1.45 (95% CI $1.30 – $1.60) and Sulphadoxine – Pyri-
methamine was $0.43 (95% CI $0.34 – $0.52), the lowest
mean price of any anti-malaria treatment. One Artesunate
product was surveyed, priced at $0.94. There were no
significant differences in price between urban and rural
drug outlets for any specific anti-malarial product.
However, there was a significant difference in price be-
tween a QAACT and its NAACT counterpart between
the urban and rural setting. Quality Assured AL was the
only chemical composition that was significantly cheaper
than its Non-Assured counterpart (Table 4). This was
true in the urban and rural setting. Quality Assured
ASAQ, however, was not cheaper than the Non-Assured
ASAQ in urban or rural settings.
Discussion
This research describes the state of the anti-malarial
market in Kintampo area of Ghana in 2014, about 2
years after the end of the AMFm program. Tracking the
effect of a subsidy such as this allows for a better alloca-
tion of resources by determining if the amount co-paid
by the Global Fund adequately lowered the price to an
acceptable price compared to other products on the
market. Donor-funded subsidies, such as the AMFm
program from the Global Fund, require proof that there
was a measurable impact from their actions.
This study found that the availability of QAACTs was
high in the study area (>80%) about 2 years after the end
of AMFm program especially in rural areas. The high
availability of QAACTs found in this study is similar to
that found by Tougher et al. in their evaluation of AMFm
in Ghana at the end of AMFm program [11]. In the same
evaluation Tougher et al. concluded that AMFm had
made a significant impact on the availability of QAACTs
especially in the public sector [11]. Coming after the
Tougher et al. study, this study therefore provides an
Table 3 Availability of ACTs in Urban and Rural Settings of the Kintampo North Municipality and South District
Product Urban Drug outlets Rural Drug outlets All Drug outlets
Product Available (%) Product Available (%) Product Available (%)
Quality Assured AL 75.0 87.1 * 81.0 *
Non-Assured AL 71.9 12.9 42.9
Quality Assured ASAQ 59.4 * 29.0 * 44.4 *
Non-Assured ASAQ 21.9 0.0 11.1
Any QAACT 84.4 93.6 * 88.9 *
Any NAACTa 75.0 16.1 46.0
*Signifies chi-squared value between Quality Assured group and Non-Assured group is below p < .05 level of significance
aThis statistic excludes dihydroartemisinin – piperaquine (DHAP), an ACT that was sold in Ghana but not as a QAACT. For that reason, DHAP is not compared in
this table
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assurance of a sustained effect of AMFm and meets the
estimated bench mark of success of the program about 2
years after its conclusion [19]. Similar observations have
been documented in other parts of Ghana [20, 21].
A QAACT as a top-selling product mentioned by drug
outlet attendants in the entire study area signals the suc-
cess of one of the AMFm program’s goals to encourage
the sale of ACTs to treat malaria. However, SP and
Quinine, neither being recommended treatments, were
both highly sold in rural drug outlets. Customers prefer
products they have used successfully in the past and
were less expensive. Quinine is the recommended treat-
ments for patients with complicated or severe malaria as
well as the treatment of uncomplicated malaria in the
first trimester of pregnancy [7]. SP is used for IPT for
pregnant women. The popularity of these two products
is likely explained by its historical use and lower price of
SP [22]. These data of top selling products are important
for the National Malaria Control Programs to review to
understand the preference of the community members
in their choice of anti-malarial products for malaria
control. On the other hand, the availability of other
treatment methods, such as amodiaquine, SP and Quin-
ine, in the drug outlets of the study area is worrying.
The mean price of QAACTs were significantly cheaper
than their Non-Assured counterparts across all drug
outlets where they were available. This observation is
similar to that observed by Ansah et al. [20] and meets
the price bench mark for the success of AMFm as found
by Tougher et al. [11]. The cheaper price of the
QAACTs may have benefitted the consumer as intended.
In a study by Adjei et al. [21] in Ghana, community
members found ACTs to be affordable during the imple-
mentation of AMFm. In addition, there was no significant
price difference between urban and rural settings for any
ACT However, non-ACT products were significantly
cheaper and available in rural areas compared with that in
urban areas of the study. It is likely that there is still
demand for non-ACT products by sections of the popula-
tion who still cannot afford ACTs, especially in rural areas.
This suggests that AMFm may have generally had a lesser
impact in replacing non-ACT products in compared rural
areas compared with urban areas.
Limitations
This research could not conclude that in the absence of
the subsidy from the AMFm program, the availability of
NAACTs would remain as low in rural drug outlets.
QAACTs could be acting as a substitute good that would
be replaced by NAACTs if the subsidy from the Global
Fund to decrease the price of QAACTs never existed.
The method to determine the top selling products did not
require sales data or confirmation from the sales records of
the drug outlets. Only verbal confirmation from the attend-
ant was required, introducing the possibility of a response
bias. The attendant may have been inclined to respond that
a QAACT is the top selling product because they are aware
that it is recommended for malaria treatment.
Conclusion
During the study period of this research, QAACTs were
more available and were cheaper than NAACTs in the
Kintampo North District and Kintampo South Munici-
pality. The mean price of a QAACT was uniform across
urban and rural areas and was slightly higher than the
price of non-ACT treatments available.
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